CJC-1295 + Ipamorelin for menopause: sleep, body composition, and growth hormone

Growth hormone naturally declines with age — by the time a woman reaches menopause, her endogenous GH output is roughly a third of what it was at 25. That decline contributes to reduced deep sleep, slower recovery, thinner skin, and a shift in body composition toward less muscle and more fat. CJC-1295 combined with Ipamorelin is the most widely used protocol for physiologically restoring GH secretion in midlife adults.

What each peptide does

CJC-1295 is a growth hormone-releasing hormone (GHRH) analog — it tells the pituitary to release GH. Ipamorelin is a growth hormone secretagogue that works on a separate receptor (the ghrelin/GHSR pathway) to amplify the same signal without stimulating cortisol, prolactin, or hunger the way older secretagogues did. Together they produce a stronger, cleaner GH pulse than either alone.

Why this matters in menopause

• Deep (slow-wave) sleep is when GH is naturally released — and deep sleep collapses in perimenopause
• GH supports lean muscle mass, which supports insulin sensitivity and resting metabolic rate
• GH-driven IGF-1 supports collagen synthesis (skin, tendons, joints)
• Restoring physiologic GH pulses often improves sleep depth, morning energy, and recovery from training

Important distinction: this is not HGH

CJC-1295 + Ipamorelin does not deliver exogenous growth hormone. It amplifies your own pituitary output within physiologic pulses. That means the ceiling is your own biology — you cannot overshoot the way you can with injected recombinant HGH, which is why the safety profile is meaningfully better and why it is legally distinct from HGH prescribing.

What the evidence shows

Studies of CJC-1295 in healthy adults show sustained increases in GH and IGF-1 with weekly dosing. Ipamorelin studies show clean GH pulses without cortisol elevation. Combined protocols have been used clinically for over a decade in longevity and sports-medicine settings. Large randomized trials in specifically menopausal populations are limited — most clinical experience is drawn from anti-aging practices and case series.

How it is typically used

Standard protocols use nightly subcutaneous injections 5 nights per week for a defined cycle (12–16 weeks), then a break. Timing matters — dosing before bed amplifies the natural GH pulse of early deep sleep. It is not a "take forever" peptide; the goal is a therapeutic cycle followed by a break to preserve pituitary responsiveness.

Cautions

CJC-1295 + Ipamorelin is not appropriate for women with active malignancy, uncontrolled diabetes, or a history of pituitary disease. It should be prescribed and monitored by a physician who tracks IGF-1 levels through the cycle. Compounded through 503A pharmacies; never sourced from consumer channels.

The bottom line

For menopausal women with well-optimized hormones who still struggle with sleep depth, recovery, or body composition, CJC-1295 + Ipamorelin is one of the most-used and best-tolerated peptide protocols. It complements — never replaces — HRT, strength training, and protein-forward nutrition. See our [CJC-1295 + Ipamorelin reference sheet](/peptides-reference/cjc-1295-ipamorelin) for full dosing and monitoring details.

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026